Poly Medicure Ltd

AI
Poly Medicure Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Poly Medicure Ltd

₹ 1,681 -0.70%
13 Nov - close price
polymedicure.com BSE: 531768 NSE: POLYMED
About

Poly Medicure Limited is an India-based manufacturer and exporter of medical devices. The Company exports plastic medical disposables/surgical devices.[1]

Key Points

Product Portfolio:[1]
PML is a medical devices company
with a product portfolio comprised of
200+ SKUs of medical devices across
12 specialties including therapy, oncology, anesthesia and respiratory care, urology, gastroenterology, blood management and
blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices, and others.

Website BSE NSE
  • Market Cap ₹ 17,041 Cr.
  • Current Price ₹ 1,681
  • High / Low ₹ 2,024 / 1,182
  • Stock P/E 53.9
  • Book Value ₹ 322
  • Dividend Yield 0.21 %
  • ROCE 12.5 %
  • ROE 9.80 %
  • Face Value ₹ 5.00
Edit ratios

Pros

Cons

  • Company has a low return on equity of 13.3% over last 3 years.
  • Debtor days have increased from 83.9 to 103 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies

Part of BSE 500 BSE Healthcare Nifty 500 BSE 250 SmallCap Index BSE 400 MidSmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
337 340 378 385 420 424 441 403 444 494 535 525 581
253 249 282 281 305 310 321 298 329 382 424 400 443
Operating Profit 84 90 96 104 115 114 119 106 115 111 110 125 138
OPM % 25% 27% 26% 27% 27% 27% 27% 26% 26% 23% 21% 24% 24%
15 17 15 17 27 24 27 43 35 21 19 35 30
Interest 2 3 3 3 3 3 2 3 3 6 6 6 7
Depreciation 16 16 16 20 21 21 21 23 25 29 38 36 35
Profit before tax 81 88 92 98 118 113 123 123 122 98 85 117 125
Tax % 23% 26% 26% 25% 26% 25% 25% 24% 25% 27% 24% 27% 24%
62 65 68 74 87 85 92 93 92 71 65 85 95
EPS in Rs 6.48 6.78 7.12 7.71 8.63 8.41 9.06 9.19 9.06 7.00 6.54 8.49 9.39
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
390 411 454 519 610 687 785 922 1,115 1,375 1,669 1,875 2,134
304 323 361 397 479 520 569 707 847 1,014 1,213 1,429 1,650
Operating Profit 86 88 93 122 131 166 216 215 267 361 456 446 484
OPM % 22% 21% 21% 23% 22% 24% 28% 23% 24% 26% 27% 24% 23%
28 8 14 16 20 21 22 40 38 60 94 119 106
Interest 10 10 8 12 14 20 11 6 11 14 14 21 26
Depreciation 19 21 24 29 37 41 48 54 57 63 83 116 138
Profit before tax 85 65 75 97 100 126 180 195 237 344 453 427 426
Tax % 27% 27% 27% 27% 35% 24% 25% 25% 25% 25% 25% 25%
62 48 55 71 65 96 136 147 179 258 339 321 316
EPS in Rs 7.07 5.47 6.25 8.00 7.41 10.86 14.17 15.28 18.69 26.91 33.41 31.78 31.42
Dividend Payout % 18% 27% 40% 25% 27% 18% 18% 16% 16% 11% 10% 11%
Compounded Sales Growth
10 Years: 16%
5 Years: 19%
3 Years: 19%
TTM: 25%
Compounded Profit Growth
10 Years: 20%
5 Years: 16%
3 Years: 19%
TTM: -13%
Stock Price CAGR
10 Years: 24%
5 Years: 13%
3 Years: 4%
1 Year: -13%
Return on Equity
10 Years: 15%
5 Years: 14%
3 Years: 13%
Last Year: 10%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 22 22 44 44 44 44 48 48 48 48 51 51 51
Reserves 174 207 227 294 337 391 918 1,040 1,194 1,422 2,715 3,055 3,215
79 82 101 133 161 207 137 127 149 174 180 354 412
89 76 85 94 112 126 121 163 187 215 246 401 478
Total Liabilities 364 387 457 565 654 767 1,224 1,377 1,577 1,859 3,192 3,861 4,155
165 182 207 265 306 363 426 488 635 867 1,084 1,694 1,861
CWIP 10 14 20 18 19 25 21 43 78 76 101 99 110
Investments 4 4 3 17 8 25 354 346 126 167 1,076 755 746
185 187 227 264 321 354 422 499 738 748 930 1,313 1,438
Total Assets 364 387 457 565 654 767 1,224 1,377 1,577 1,859 3,192 3,861 4,155

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
63 63 56 75 106 131 119 123 191 266 233 246
-59 -31 -56 -88 -101 -109 -436 -85 -179 -241 -1,187 -224
-6 -31 -0 16 -5 -21 317 -35 -13 -20 951 20
Net Cash Flow -2 1 0 3 1 1 0 3 -1 5 -3 43
Free Cash Flow 13 31 -0 -7 31 25 24 -31 -48 -9 -97 -59
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 101% 88% 79% 80% 102% 100% 75% 80% 93% 94% 71% 78%

Ratios

Consolidated / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 59 74 77 79 77 68 72 82 77 72 76 103
Inventory Days 148 114 194 161 186 241 217 218 237 205 233 323
Days Payable 101 76 131 96 123 142 111 115 105 89 70 91
Cash Conversion Cycle 106 111 140 144 139 166 179 185 209 188 239 335
Working Capital Days 25 35 55 71 56 42 74 81 69 54 75 105
ROCE % 30% 26% 24% 26% 22% 25% 22% 17% 18% 24% 18% 12%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Number of countries served
count ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Sales associates
count ・Standalone data
Number of distributors
count ・Standalone data
Number of manufacturing plants
count ・Standalone data
Number of patents granted
count ・Standalone data
New product launches (annual)
count
Infusion Therapy share of revenue
%
Renal Care share of revenue
%
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
53.17% 53.14% 66.02% 62.56% 62.44% 62.44% 62.44% 62.42% 62.42% 62.42% 62.42% 62.41%
14.10% 12.37% 9.91% 11.88% 12.33% 11.46% 11.41% 9.77% 9.41% 5.92% 5.56% 5.36%
5.46% 7.21% 9.34% 12.33% 11.66% 11.96% 11.72% 13.53% 13.84% 15.60% 16.08% 15.90%
27.28% 27.25% 14.72% 13.23% 13.57% 14.13% 14.43% 14.28% 14.34% 16.08% 15.94% 16.33%
No. of Shareholders 36,05336,71236,85238,35260,68665,58371,14264,40067,75073,41473,64374,153

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls